Drug Development

Alnylam presents phase I data for ALN-RSV01

Published in Drug Week, May 26th, 2006

Alnylam Pharmaceuticals, Inc., (ALNY) announced that Alnylam and collaborators presented data from its phase I trials with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection, at the 2006 Pediatric Academic Societies' (PAS) annual meeting held in San Francisco.

The phase I trials, conducted in the U.S. and in Europe, were designed to assess the safety and pharmacology of ALN-RSV01 in healthy volunteers.

RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract. RSV infects nearly every child at least once by the age of 2 years and is a major cause of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry